CN1867331B - 作为TNF-α调节剂的沙利度胺类似物 - Google Patents

作为TNF-α调节剂的沙利度胺类似物 Download PDF

Info

Publication number
CN1867331B
CN1867331B CN2004800268113A CN200480026811A CN1867331B CN 1867331 B CN1867331 B CN 1867331B CN 2004800268113 A CN2004800268113 A CN 2004800268113A CN 200480026811 A CN200480026811 A CN 200480026811A CN 1867331 B CN1867331 B CN 1867331B
Authority
CN
China
Prior art keywords
sulfur
chemical compound
oxygen
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800268113A
Other languages
English (en)
Chinese (zh)
Other versions
CN1867331A (zh
Inventor
奈杰尔·H·格雷格
哈罗德·霍洛韦
阿诺德·布罗西
朱晓翔
托尼·乔达诺
于乾升
威廉·D·菲格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goverment Of United States, AS REPRESENTED BY SECRETARY D
Original Assignee
Goverment Of United States, AS REPRESENTED BY SECRETARY D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goverment Of United States, AS REPRESENTED BY SECRETARY D filed Critical Goverment Of United States, AS REPRESENTED BY SECRETARY D
Publication of CN1867331A publication Critical patent/CN1867331A/zh
Application granted granted Critical
Publication of CN1867331B publication Critical patent/CN1867331B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2004800268113A 2003-09-17 2004-09-17 作为TNF-α调节剂的沙利度胺类似物 Expired - Fee Related CN1867331B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50472403P 2003-09-17 2003-09-17
US60/504,724 2003-09-17
PCT/US2004/030506 WO2005028436A2 (en) 2003-09-17 2004-09-17 Thalidomide analogs as tnf-alpha modulators

Publications (2)

Publication Number Publication Date
CN1867331A CN1867331A (zh) 2006-11-22
CN1867331B true CN1867331B (zh) 2010-05-26

Family

ID=34375538

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800268113A Expired - Fee Related CN1867331B (zh) 2003-09-17 2004-09-17 作为TNF-α调节剂的沙利度胺类似物

Country Status (9)

Country Link
US (2) US7973057B2 (enExample)
EP (1) EP1663223B1 (enExample)
JP (1) JP4943845B2 (enExample)
CN (1) CN1867331B (enExample)
AU (1) AU2004274474B2 (enExample)
BR (1) BRPI0414497A (enExample)
CA (2) CA2538864C (enExample)
SG (1) SG133603A1 (enExample)
WO (1) WO2005028436A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2929331B2 (ja) * 1990-07-18 1999-08-03 丸善石油化学株式会社 トラクションドライブ用流体
US20060063766A1 (en) 2004-07-15 2006-03-23 Molino Bruce F Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin
CN100383139C (zh) 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
MX2009001989A (es) * 2006-08-30 2009-03-09 Celgene Corp Compuestos de isoindolina 5-substituidos.
AU2013260742B2 (en) * 2007-03-20 2016-06-16 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
US8153659B2 (en) * 2007-03-20 2012-04-10 Celgene Corporation 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same
US7723301B2 (en) * 2007-08-29 2010-05-25 The Board Of Trustees Of The University Of Arkansas Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
JP2012526823A (ja) 2009-05-12 2012-11-01 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用
PE20120373A1 (es) * 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
SI3202460T1 (sl) * 2010-02-11 2019-10-30 Celgene Corp Arilmetoksi izoindolin derivati in sestavki, ki jih obsegajo in metode za uporabo le-teh
US9193989B2 (en) 2010-06-18 2015-11-24 Taiho Pharmaceutical Co., Ltd. PRPK-TPRKB modulators and uses thereof
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
WO2013089278A1 (en) 2011-12-14 2013-06-20 Taiho Pharmaceutical Co., Ltd. Recombinant prpk-tprkb and uses thereof
US9383644B2 (en) 2014-09-18 2016-07-05 Heraeus Precious Metals North America Daychem LLC Sulfonic acid derivative compounds as photoacid generators in resist applications
WO2016065980A1 (zh) 2014-10-30 2016-05-06 康朴生物医药技术（上海）有限公司 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用
US9477150B2 (en) 2015-03-13 2016-10-25 Heraeus Precious Metals North America Daychem LLC Sulfonic acid derivative compounds as photoacid generators in resist applications
JP6930969B2 (ja) * 2015-07-08 2021-09-01 ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療
AU2016330967B2 (en) 2015-09-30 2021-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thalidomide analogs and methods of use
EP3429996A4 (en) * 2016-03-16 2020-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. SMALL MOLECULES AGAINST CEREBLON TO IMPROVE THE FUNCTION OF EFFECTOR T CELLS
AU2017366514B2 (en) * 2016-11-24 2021-01-21 Ganzhou Hemay Pharmaceutical, Co., Ltd Piperidine-2,6-dione derivative and treatment for ulcerative colitis
KR20200086278A (ko) 2017-10-18 2020-07-16 노파르티스 아게 선택적 단백질 분해를 위한 조성물 및 방법
SG11202012464WA (en) 2018-07-11 2021-01-28 H Lee Moffitt Cancer Center And Research Institute Inc Dimeric immuno-modulatory compounds against cereblon-based mechanisms
US11324731B2 (en) 2018-09-13 2022-05-10 City Of Hope TXNIP-TRX complex inhibitors and methods of using the same
WO2020102195A1 (en) 2018-11-13 2020-05-22 Biotheryx, Inc. Substituted isoindolinones
CN111601789A (zh) * 2018-12-20 2020-08-28 江苏凯迪恩医药科技有限公司 一种含氮杂环化合物、其制备方法及应用
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
CN114641337A (zh) * 2019-08-27 2022-06-17 密歇根大学董事会 Cereblon e3连接酶抑制剂
KR102783667B1 (ko) 2019-10-24 2025-03-21 삼성전자 주식회사 전자 장치 및 그의 디스플레이 동작 제어 방법
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
TW202140448A (zh) * 2020-01-16 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 並環醯亞胺類衍生物、其製備方法及其在醫藥上的應用
EP4112614A4 (en) * 2020-02-25 2023-09-06 Shanghaitech University Glutarimide skeleton-based compounds and application thereof
KR20220055171A (ko) * 2020-10-26 2022-05-03 주식회사 아이비스바이오 포말리도마이드로부터 3,6'-디티오포말리도마이드를 선택적으로 합성하는 방법
US20240166647A1 (en) * 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
EP4484418A1 (en) * 2022-02-25 2025-01-01 Aevis Bio, Inc. Use of novel pomalidomide derivative for treating brain disease
AR130961A1 (es) 2022-11-04 2025-02-05 Bristol Myers Squibb Co Compuestos y su uso para el tratamiento de hemoglobinopatías
WO2025016351A1 (zh) * 2023-07-14 2025-01-23 标新生物医药科技(上海)有限公司 基于硫代的戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1049283A (en) * 1962-04-14 1966-11-23 Distillers Co Yeast Ltd Substituted butyro-lactones and -thiolactones
US3320270A (en) * 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3794641A (en) * 1970-11-10 1974-02-26 Nehezvegyipari Kutato Intezet Substituted phthalimido-1,3,5-triazines
WO2002068414A2 (en) * 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830991A (en) 1954-05-17 1958-04-15 Gruenenthal Chemie Products of the amino-piperidine-2-6-dione series
GB962857A (en) 1961-12-04 1964-07-08 Distillers Co Yeast Ltd Process for the production of imides
US3314953A (en) 1964-03-16 1967-04-18 Richardson Merrell Inc 1-substituted-3-phthalimido-2, 5-dioxopyrrolidines
US3560495A (en) 1965-05-08 1971-02-02 Ernst Frankus 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6
IL25595A (en) 1965-05-08 1971-01-28 Gruenenthal Chemie New history of cyclic amide compounds and process for the production of these compounds
US4067718A (en) 1975-11-12 1978-01-10 American Cyanamid Company Method for controlling the relative stem growth of plants
US4291048A (en) 1978-07-06 1981-09-22 Joseph Gold Method of treating tumors and cancerous cachexia with L-tryptophan
US5354690A (en) 1989-07-07 1994-10-11 Karl Tryggvason Immunological methods for the detection of the human type IV collagen α5 chain
US5902790A (en) 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
GB9311281D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
HK1005188A1 (en) 1991-04-17 1998-12-24 Grunenthal Gmbh New thalidomide derivatives, method of manufacture and use thereof in medicaments
US6096768A (en) 1992-01-28 2000-08-01 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5443824A (en) 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
DE4422237A1 (de) 1994-06-24 1996-01-04 Gruenenthal Gmbh Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
RU2164514C2 (ru) 1994-12-30 2001-03-27 Селджин Корпорейшн Имид/амидные простые эфиры, фармацевтическая композиция на их основе и способ снижения уровня фнока у млекопитающих
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5783605A (en) 1995-02-27 1998-07-21 Kuo; Sheng-Chu Helper inducers for differentiation therapy and chemoprevention of cancer
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
DE19613976C1 (de) 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
CA2251060C (en) 1996-04-09 2006-09-12 Grunenthal Gmbh Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
EP0914123A4 (en) 1996-05-29 2000-10-11 Prototek Inc THALIDOMIDE PRODUCTS AND METHODS OF USING SAID PRODUCTS AS T CELL MODIFIERS
DE69740140D1 (de) 1996-07-24 2011-04-14 Celgene Corp Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
ES2313154T3 (es) 1996-11-05 2009-03-01 The Children's Medical Center Corporation Composiciones que comprenden talodimina y dexametasona para el tratamiento de cancer.
CA2274958A1 (en) 1996-12-13 1998-06-18 Gerald Wayne Becker Inhibitors of the enzymatic activity of psa
DE19703763C1 (de) 1997-02-01 1998-10-01 Gruenenthal Gmbh Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
RU2108786C1 (ru) 1997-09-15 1998-04-20 Клавдия Степановна Евланенкова Средство для лечения онкологических больных
DE19743968C2 (de) 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen
EP1091726A2 (en) 1998-05-11 2001-04-18 EntreMed, Inc. Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
JP2003505337A (ja) 1998-05-15 2003-02-12 アストラゼネカ アクチボラグ サイトカインにより仲介される疾病を処置するためのベンズアミド誘導体
DE19843793C2 (de) 1998-09-24 2000-08-03 Gruenenthal Gmbh Substituierte Benzamide
US20030013739A1 (en) 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
DE50001522D1 (de) 1999-03-31 2003-04-30 Gruenenthal Gmbh Stabile wässrige Lösung von 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dion
US20010041716A1 (en) 1999-12-02 2001-11-15 Laing Timothy J. Compositions and methods for locally treating inflammatory diseases
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
AU2002253795B2 (en) 2000-11-30 2007-02-01 The Children's Medical Center Corporation Synthesis of 4-Amino-Thalidomide enantiomers
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
NZ531294A (en) 2001-08-06 2005-11-25 Childrens Medical Center Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
EP2105135B1 (en) 2002-05-17 2014-10-22 Celgene Corporation Pharmaceutical compositions for treating cancer
CN100488959C (zh) 2003-03-27 2009-05-20 天津和美生物技术有限公司 水溶性的酞胺哌啶酮衍生物
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1049283A (en) * 1962-04-14 1966-11-23 Distillers Co Yeast Ltd Substituted butyro-lactones and -thiolactones
US3320270A (en) * 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3794641A (en) * 1970-11-10 1974-02-26 Nehezvegyipari Kutato Intezet Substituted phthalimido-1,3,5-triazines
WO2002068414A2 (en) * 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Andrzej orzeszko, et al.Tumor necrosis factor-alpha production-regulating activityofphthalimide derivatives in genetically modifiedmurinemelanoma cells B78H1.IL FARMACO58 5.2003,58(5),371-376.
Andrzej orzeszko, et al.Tumor necrosis factor-alpha production-regulating activityofphthalimide derivatives in genetically modifiedmurinemelanoma cells B78H1.IL FARMACO58 5.2003,58(5),371-376. *
Brian L. Bray, et al.Improved procedures for the preparation of(+)-(1R,2S,4R)-4-amino-2-hydroxy-1-hydroxymethylcyclopentane.Tetrahedron Letters36 25.1995,36(25),4483-4486.
Brian L. Bray, et al.Improved procedures for the preparation of(+)-(1R,2S,4R)-4-amino-2-hydroxy-1-hydroxymethylcyclopentane.Tetrahedron Letters36 25.1995,36(25),4483-4486. *
medicinal chemistry10 3.2002,10(3),461-479. *
Rumiko Shimazawa, et al.Antiangiogenic activity of tumor necrosis factor-a productionregulators derived from thalidomide.Biol. Pharm. Bull.22 2.1999,22(2),224-226.
Rumiko Shimazawa, et al.Antiangiogenic activity of tumor necrosis factor-a productionregulators derived from thalidomide.Biol. Pharm. Bull.22 2.1999,22(2),224-226. *
Yuichi hashimoto.Structural development of biological response modifiers basedon thalidomide.Bioorganic & medicinal chemistry10 3.2002,10(3),461-479.
Yuichi hashimoto.Structural development of biological response modifiers basedon thalidomide.Bioorganic &amp *

Also Published As

Publication number Publication date
AU2004274474A1 (en) 2005-03-31
CN1867331A (zh) 2006-11-22
JP4943845B2 (ja) 2012-05-30
BRPI0414497A (pt) 2006-11-14
CA2538864A1 (en) 2005-03-31
US8546430B2 (en) 2013-10-01
EP1663223B1 (en) 2014-01-01
US20060211728A1 (en) 2006-09-21
CA2808646C (en) 2016-08-23
AU2004274474B2 (en) 2011-03-10
JP2007505922A (ja) 2007-03-15
WO2005028436A3 (en) 2005-05-19
EP1663223A2 (en) 2006-06-07
SG133603A1 (en) 2007-07-30
US7973057B2 (en) 2011-07-05
US20110245210A1 (en) 2011-10-06
CA2538864C (en) 2013-05-07
CA2808646A1 (en) 2005-03-31
WO2005028436A2 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
CN1867331B (zh) 作为TNF-α调节剂的沙利度胺类似物
US8853253B2 (en) Thalidomide analogs
JP5156378B2 (ja) ＭＤＭ２とｐ５３の間の相互作用の阻害剤
CA2433021C (en) Isoindole-imide compounds, compositions, and uses thereof
TWI746562B (zh) 磺醯胺化合物或其鹽
CN110770242B (zh) 作为vanin抑制剂的杂芳族化合物
JP2010514689A (ja) 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
MX2015002807A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble.
WO2013161919A1 (ja) Ｔｒｋ阻害化合物
AU2014234909B2 (en) Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors
WO2011146591A1 (en) Substituted hydroxamic acids and uses thereof
CZ2003284A3 (cs) 3,4-Dihydroisochinolinový derivát a farmaceutické činidlo obsahující tento derivát jako účinnou složku
KR102404865B1 (ko) 항종양제
CN105339350B (zh) 二氢吡啶酮mgat2抑制剂
WO2017049462A1 (zh) 一类新型的flt3激酶抑制剂及其用途
EP3452045A1 (en) Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
TW200916458A (en) Heterocyclic compounds and methods of use thereof
TW201113269A (en) New compounds, pharmaceutical composition and methods relating thereto
WO2005105743A1 (ja) 含窒素複素環化合物およびその医薬用途
JP7214086B2 (ja) 二環式コア部分を有する新規ｌｘｒモジュレーター
WO2006051826A1 (ja) 含窒素複素環化合物およびその医薬用途
WO2021259049A1 (zh) 吲哚类衍生物及其制备方法和应用
JP2022553282A (ja) Ｔｒｅｋ（ｔｗｉｋ関連ｋ＋チャネル）チャネル機能のモジュレータ
CN101405281B (zh) Mdm2和p53相互作用的抑制剂
KR20240066906A (ko) 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100526

Termination date: 20170917

CF01 Termination of patent right due to non-payment of annual fee